Elliott Dasenbrook, MD

Elliott Dasenbrook, MD MHS, is the Director of the Cleveland Clinic Adult Cystic Fibrosis Program and the Bronchiectasis Center in the Respiratory Institute. Dr. Dasenbrook trained in the care of individuals living with cystic fibrosis at Johns Hopkins Hospital under the mentorship of Dr. Michael Boyle. Dr. Dasenbrook is known around the world for his expertise in the management of difficult to treat infections. As a member of a multidisciplinary CF team at the Cleveland Clinic, Dr. Dasenbrook partners with his patients to meet their individual goals in order to optimize health outcomes. He has been involved in the care of individuals with CF for more than 10 years and believes that the most important member of the CF team is the patient.

Dr. Dasenbrook is a member of the National Cystic Fibrosis Access to Care Committee which is comprised of patients, family members, and clinicians to identify barriers and solutions to improve access to care in the United States. He also participates in Research and is the Associate Chair of the National CF Foundation Patient Registry Committee.

For more informationabout the Cleveland Clinic CF program or an appointment, please call 216.442.4623 (GOCF)

Dr. Dasenbrook has taken the skills he has learned in the care of cystic fibrosis lung disease and applied it to individuals with bronchiectasis and pulmonary nontuberculous mycobacteria (NTM) infectious such as Mycobacteriumavium complex (MAC) and Mycobacterium abscessus. The focus in this clinic is diagnosing the underlying cause of bronchiectasis (such as primary ciliary dyskinesia (PCD)) and expert management of bronchiectasis lung disease.

The goal of the clinic is to improve patient day to day quality of life through reduction of daily cough, mucus production,and number of respiratory exacerbations. To achieve these goals, the Bronchiectasis team at the Cleveland Clinic hasadvanced knowledge in airway clearance techniques and devices, inhaled medications to treat airway infections, and treatment of airway inflammation. For patients who have NTM, Dr. Dasenbrook collaborates with his colleagues from Infectious Disease who also specialize intreatment of pulmonary NTM. In addition to clinical care, Dr. Dasenbrook is active in research for non-CF bronchiectasis.

Education & Professional Highlights

Appointed
2015

Education & Fellowships

Fellowship - Johns Hopkins University School of Medicine
Pulmonary & Critical Care Medicine
Baltimore, MD USA
2009

Residency - Loyola University Stritch School of Medicine
Internal Medicine
Chicago, IL USA
2005

Medical Education - Loyola University Stritch School of Medicine
MD
Chicago, IL USA
2001

Undergraduate - Loyola University
Chicago, IL USA
1997

Certifications

Internal Medicine - Pulmonary Disease
Internal Medicine - Critical Care Medicine

Specialty Interests

Adult Cystic Fibrosis, Bronchiectasis, Nontuberculous Mycobacterial Pulmonary Disease, Primary Ciliary Dysfunction, and Allergic Bronchopulmonary Aspergillosis

Research & Publications

See publications for Elliott Dasenbrook, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 2/15/2023, Dr. Dasenbrook has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Coming to a Cleveland Clinic location?

Primary Location

Cleveland Clinic Main Campus

Additional Locations

Specialty in Diseases & Conditions

Insurance

Is Cleveland Clinic Part of Your Insurance?